Adding Pertuzumab to Adjuvant Therapy Improves DFS in Early Breast Cancer

Share this content:
Adding pertuzumab (Perjeta) to adjuvant trastuzumab (Herceptin) and chemotherapy improved invasive disease-free survival.
Adding pertuzumab (Perjeta) to adjuvant trastuzumab (Herceptin) and chemotherapy improved invasive disease-free survival.

Adding pertuzumab (Perjeta) to adjuvant trastuzumab (Herceptin) and chemotherapy improved invasive disease-free survival among patients with HER2-positive early breast cancer, according to an announcement by the drug's developer, Genentech.1

Preliminary results from the multicenter, double-blind, phase 3 APHINITY trial (ClinicalTrials.gov Identifier: NCT01358877) showed that treatment with the combination of pertuzumab, trastuzumab, and chemotherapy achieved a significant reduction in the risk of recurrence of invasive disease or death compared with trastuzumab plus chemotherapy alone.

The safety profile of pertuzumab in combination with trastuzumab and chemotherapy was consistent with previous reports; investigators have not detected any new safety signals.

RELATED: Analysis of Breast Cancer-related Information on NCI Center Websites

The study enrolled 4805 patients with operable, HER2-positive, early breast cancer and randomly assigned them 1:1 to receive 6 to 8 cycles of an anthracycline or non-anthracycline-containing chemotherapy regimen with trastuzumab and pertuzumab or placebo, followed by trastuzumab plus pertuzumab or placebo every 3 weeks for 1 year.

Investigators plan to submit full results from the APHINITY trial for presentation at an upcoming medical meeting in 2017.

Reference

  1. Phase III APHINITY study shows Genentech's Perjeta regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin and chemotherapy [news release]. South San Francisco, CA: Genentech; March 1, 2017. https://www.gene.com/media/press-releases/14655/2017-03-01/phase-iii-aphinity-study-shows-genentech. Accessed March 2, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters